- Home
- CTLP vs KROS Comparison
CTLP vs KROS Comparison
Compare CTLP & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTLP
- KROS
- Stock Information
- Founded
- CTLP 1992
- KROS 2015
- Country
- CTLP United States
- KROS United States
- Employees
- CTLP N/A
- KROS N/A
- Industry
- CTLP EDP Services
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- CTLP Technology
- KROS Health Care
- Exchange
- CTLP Nasdaq
- KROS Nasdaq
- Market Cap
- CTLP 574.8M
- KROS 465.2M
- IPO Year
- CTLP N/A
- KROS 2020
- Fundamental
- Price
- CTLP $8.03
- KROS $10.04
- Analyst Decision
- CTLP Strong Buy
- KROS Buy
- Analyst Count
- CTLP 4
- KROS 12
- Target Price
- CTLP $12.50
- KROS $27.86
- AVG Volume (30 Days)
- CTLP 487.4K
- KROS 708.7K
- Earning Date
- CTLP 05-08-2025
- KROS 05-07-2025
- Dividend Yield
- CTLP N/A
- KROS N/A
- EPS Growth
- CTLP N/A
- KROS N/A
- EPS
- CTLP 0.19
- KROS N/A
- Revenue
- CTLP $285,112,000.00
- KROS $3,550,000.00
- Revenue This Year
- CTLP $18.00
- KROS $65.83
- Revenue Next Year
- CTLP $15.55
- KROS $1.36
- P/E Ratio
- CTLP $42.43
- KROS N/A
- Revenue Growth
- CTLP 12.88
- KROS 2250.99
- 52 Week Low
- CTLP $5.75
- KROS $9.41
- 52 Week High
- CTLP $11.36
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- CTLP 44.51
- KROS 35.08
- Support Level
- CTLP $7.31
- KROS $11.18
- Resistance Level
- CTLP $8.08
- KROS $11.63
- Average True Range (ATR)
- CTLP 0.36
- KROS 0.42
- MACD
- CTLP 0.05
- KROS -0.09
- Stochastic Oscillator
- CTLP 77.84
- KROS 26.69
About CTLP Cantaloupe Inc.
Cantaloupe Inc operates in the small ticket electronic payments industry. It provides wireless, cashless, micro-transactions, and networking services within the unattended Point of Sale (POS) market. Its products and services portfolio consists of ePort Cashless devices, eSuds, EnergyMisers, and Value-added services which include Loyalty and Prepaid, Intelligent Vending, and others. The company offers services to different industries covering car wash, taxi and transportation, laundry, vending, kiosk, amusement, and arcade. The company derives revenue from the sale or lease of equipment and services to the small ticket, unattended POS market, and the majority of its revenue is derived from subscription and transaction fees.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.